title: Reduced thrombin generation and soluble P-selectin after intravenous enoxaparin during PCI.
abstract: OBJECTIVE
  The objective of our study was to identify changes in the coagulation and serum concentration of soluble P-selectin (sP-sel) after i.v. bolus of 0.75 mg/kg enoxaparin in a group of 33 patients during PCI.
  
  
  RESULTS
  As compared to baseline, i.v. enoxaparin increased anti -Xa activity and FIIa inhibition together with APTT and thrombin time tests within 20 min, that persisted for 60 min. At 6 h, the results of all tests had returned to baseline. In contrast, the level of prothrombin fragments (F1 + 2) decreased persistingly for a period of 6 h (baseline 1.19 ± 0.42 nmol/l, after 20 min 1.03 ± 0.46 nmol/l, after 60 min 1.06 ± 0.43 nmol/l, after 6 h 0.95 ± 0.40 nmol/l, p < 0.001 vs. baseline for all values). In addition, i.v. enoxaparin decreased serum sP-sel level (baseline 111.80 ± 37.05 ng/ml, after 20 min 87.80 ± 33.17 ng/ml, after 60 min 86.45 ± 29.15 ng/ml, after 6 h 92.24 ± 31.34 ng/ml, p < 0.001 vs. baseline value for all). sP-sel level mildly correlated with both F Xa inhibition (r = -0.275, p < 0.05) and F1 + 2 level (r = 0.274, p < 0.05).
  
  
  CONCLUSIONS
  Intravenous enoxaparin induced target F Xa inhibition (>0.6 IU/ml) for 60 min in 82% of study patients. During the 6 h of monitoring, a decrease of thrombin generation (F1 + 2) and sP-selectin levels were observed.
authors.affiliation: Center for Thrombosis Research, General Teaching Hospital, Charles University, Karlovo n. 32, Prague, 121 11, Czech Republic.
authors.forename: J
authors.initials: J
authors.lastname: Kvasnička
authors.forename: J
authors.initials: J
authors.lastname: Horák
authors.forename: Z
authors.initials: Z
authors.lastname: Zenáhlíková
authors.forename: Tomáš
authors.initials: T
authors.lastname: Kvasnička
authors.forename: S
authors.initials: S
authors.lastname: Simek
authors.forename: T
authors.initials: T
authors.lastname: Kovárník
authors.forename: I
authors.initials: I
authors.lastname: Malíková
authors.forename: A
authors.initials: A
authors.lastname: Linhart
authors.forename: M
authors.initials: M
authors.lastname: Aschermann
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000925:Anticoagulants / Q000494:pharmacology; D003324:Coronary Artery Disease / Q000628:therapy; D017984:Enoxaparin / Q000494:pharmacology*; D065427:Factor Xa Inhibitors; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000187:drug effects* / Q000378:metabolism; D010314:Partial Thromboplastin Time; D011516:Prothrombin / Q000037:antagonists & inhibitors; D013917:Thrombin / Q000187:drug effects* / Q000378:metabolism; D013918:Thrombin Time; D013997:Time Factors
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D065427:Factor Xa Inhibitors; D019007:P-Selectin; D011516:Prothrombin; C025337:Factor IIa; D013917:Thrombin